Sterol-derived compounds for the treatment of diseases associated with mitochondrial deficiency

JP2025520441A5Pending Publication Date: 2026-06-15DENDROGENIX
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
DENDROGENIX
Filing Date
2023-06-14
Publication Date
2026-06-15

AI Technical Summary

⚠Technical Problem

Current treatments for mitochondrial deficiency-related pathologies, such as autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related psychiatric conditions, ataxia, neuropathy, smoking-related brain and lung disorders, MERRF syndrome, and NARP syndrome, are limited, with no FDA-approved therapies effectively addressing mitochondrial dysfunction.

⚗Method used

Sterol-based compounds of formula (I) or their pharmaceutically acceptable salts, which improve mitochondrial dynamics, transport, and activity, are used to treat these conditions.

🎯Benefits of technology

The sterol-based compounds enhance mitochondrial function, improving metabolic activity, reducing symptoms, and potentially curing these pathologies by restoring energy production and reducing harmful substance accumulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

A sterol-based compound of formula (I) for use in the prevention, amelioration, and / or treatment of mitochondrial deficiency-related medical conditions selected from the group consisting of autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related psychosis, ataxia, neuropathy, smoking-related brain and lung disorders, MERRF syndrome, and NARP syndrome. A pharmaceutical composition comprising at least one compound of formula (I).
Need to check novelty before this filing date? Find Prior Art